BeStock  
Stocks › Biotechnology › ADRX

Adarx Pharmaceuticals ADRX

US equityMarket cap rank #2910Biotechnology
$12.79 −$1.37 (-9.68%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $12.79 0.00%
Open$14.03
Prev close$14.16
Day range$12.63 – $14.87
Volume708.8K
Market cap$1.42B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership62.3%+62.31 pts vs. prior quarter
Institutions holding26+26 vs. prior quarter
Insider trades (recent)10 buys / 0 sellsNet buying
Short interest1.76% of floatDays to cover 5.0 · as of 30 Oct 2026
Short-sale volume share23.1%5-day average of daily volume

Short-sale volume as % of daily volume

7%16%24%33%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$86.1K (10 inflow days, 10 outflow days).

Net flow by order size, last 20 sessions

+$9,118Super−$95.3KBig−$343.4KMid+$306.4KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 52.0% of shares outstanding.

Largest holders

  • OrbiMed Advisors LLC22.13%
  • Eli Lilly Investment Consulting (Shanghai) Co., Ltd.10.58%
  • SR One Capital Management, LP8.87%
  • Li Zhen5.23%
  • Zhen Li5.23%
  • Bcls Fund III Investments, Lp4.58%
  • FMR3.25%
  • TCG Crossover Management, LLC3.20%

By investor type

  • VC/PE Fund46.50%
  • Mutual Fund11.12%
  • Individual/Insider7.47%
  • Private Company4.63%
  • Hedge Fund0.03%
  • Public Company0.02%

Reported short interest has risen from 1.14% to 1.76% of float over the last 3 biweekly reports (30 Sep 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
OrbiMed Advisors LLC VC/PE Fund 2026/Q3 +24,794,024 22.1%
Eli Lilly Investment Consulting (Shanghai) Co., Ltd. VC/PE Fund 2026/Q3 +11,858,655 10.6%
FMR Mutual Fund 2026/Q3 +3,646,090 3.3%
Capital Research Mutual Fund 2026/Q3 +3,332,301 3.0%
BlackRock Mutual Fund 2026/Q3 +2,336,110 2.1%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +1,962,004 1.8%
Artal Group S.A. VC/PE Fund 2026/Q3 +1,925,794 1.7%
Franklin Resources Mutual Fund 2026/Q3 +900,000 0.8%
MFS Investment Management Mutual Fund 2026/Q3 +650,360 0.6%
abrdn plc Mutual Fund 2026/Q3 +120,000 0.1%
TD Asset Management Mutual Fund 2026/Q3 +91,770 0.1%
Jane Street Group, LLC Private Company 2026/Q3 +63,680 0.1%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +43,331 0.0%
Morgan Stanley Public Company 2026/Q3 +22,544 0.0%
Morgan Stanley Investment Management Inc. Mutual Fund 2026/Q3 +22,544 0.0%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
27 Sep 2026 OrbiMed Advisors LLC Private Acquisition +950,000 $17.00 24,205,789
27 Sep 2026 OrbiMed Advisors LLC Derivative Exercise and Retained +23,255,789 – 24,205,789
27 Sep 2026 Eli Lilly Investment Consulting (Shanghai) Co., Ltd. Derivative Exercise and Retained +11,858,655 – 11,858,655
27 Sep 2026 SR One Capital Management, LP Private Acquisition +1,600,000 $17.00 9,936,661
27 Sep 2026 SR One Capital Management, LP Derivative Exercise and Retained +8,336,661 – 9,936,661
23 Sep 2026 Mary Tagliaferri Independent Director Initial Statement of Beneficial +0 – 357,056
23 Sep 2026 Ying Huang Independent Director Initial Statement of Beneficial +0 – 267,792
23 Sep 2026 Li Zhen Chief Executive Officer Other Derivative Acquisition +1,024,152 $17.00 1,024,152
23 Sep 2026 Li Zhen Chief Executive Officer Initial Statement of Beneficial +0 – 5,960,786
23 Sep 2026 Robert Ackles Chief Human Resources Officer Other Derivative Acquisition +85,346 $17.00 85,346
23 Sep 2026 Robert Ackles Chief Human Resources Officer Initial Statement of Beneficial +0 – 335,633
23 Sep 2026 A. MacLeod Chief Scientific Officer Other Derivative Acquisition +170,692 $17.00 170,692
23 Sep 2026 A. MacLeod Chief Scientific Officer Initial Statement of Beneficial +0 – 667,023
23 Sep 2026 Ryan Fisk CFO & Chief Business Officer Other Derivative Acquisition +170,692 $17.00 170,692
23 Sep 2026 Ryan Fisk CFO & Chief Business Officer Initial Statement of Beneficial +0 – 865,864
23 Sep 2026 Rui Zhu Chief Technology Officer Other Derivative Acquisition +512,076 $17.00 512,076
23 Sep 2026 Rui Zhu Chief Technology Officer Initial Statement of Beneficial +0 – 1,277,859

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 1,801,373 1.8% 5.0
15 Oct 2026 1,903,521 1.9% 3.1
30 Sep 2026 1,163,375 1.1% 1.7

Discussion

No comments yet — be the first to weigh in on ADRX.

Sign in to join the discussion.

Scroll to Top